文献速递流行病学与生物统计临床试验与 GCP

2型糖尿病治疗疗效的年龄与性别差异:一项网络Meta分析

Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
PubMed 文献 · JAMA · 2025-01-01

该网络Meta分析纳入601项随机临床试验,评估SGLT2抑制剂、GLP-1受体激动剂和DPP4抑制剂在2型糖尿病患者中的疗效是否随年龄或性别而异。结果显示,SGLT2抑制剂在年龄较大者中降HbA1c幅度较小但心血管保护作用更强,GLP-1受体激动剂在年轻者中心血管保护作用更强;未发现一致的性别与治疗交互作用。

要点

  • SGLT2抑制剂单药、双药、三药治疗中,年龄每增加30岁,HbA1c降幅分别减少0.24%、0.17%、0.25%。
  • SGLT2抑制剂在年龄较大者中主要不良心血管事件(MACE)相对风险降低更明显(HR 0.76)。
  • GLP-1受体激动剂在年龄较大者中MACE相对风险降低更少(HR 1.47)。

核心结论

  • SGLT2抑制剂和GLP-1受体激动剂与较低的主要不良心血管事件(MACE)风险相关;年龄与治疗交互分析提示,SGLT2抑制剂在年龄较大者中心血管保护作用更强,而GLP-1受体激动剂在年轻者中心血管保护作用更强。

研究设计与样本

  • 检索MEDLINE、Embase及美国和中国临床试验注册库,截至2022年11月,并于2024年8月更新检索以获取试验结果。
  • 纳入在成人2型糖尿病患者中比较SGLT2抑制剂、GLP-1受体激动剂或DPP4抑制剂与安慰剂或活性对照的随机临床试验。
  • 共识别601项符合条件的试验,其中592项报告HbA1c(309 503例参与者,平均年龄58.9岁[SD 10.8],女性占42.3%),23项报告MACE(168 489例参与者,平均年龄64.0岁[SD 8.6],女性占35.3%)。
  • 获得103项试验的个体参与者数据(103项报告HbA1c,6项报告MACE)。
  • 采用多水平网络Meta回归模型估计年龄×治疗交互和性别×治疗交互。

主要发现

  • SGLT2抑制剂(vs 安慰剂)单药治疗中,年龄每增加30岁,HbA1c绝对降幅减少0.24%(95% CrI 0.10%至0.38%)。
  • SGLT2抑制剂双药治疗中,年龄每增加30岁,HbA1c绝对降幅减少0.17%(95% CrI 0.10%至0.24%);三药治疗中减少0.25%(95% CrI 0.20%至0.30%)。
  • GLP-1受体激动剂单药治疗中,年龄每增加30岁,HbA1c绝对降幅增加0.18%(95% CrI -0.31%至-0.05%);双药治疗中增加0.24%(95% CrI -0.40%至-0.07%);三药治疗中无一致证据(AR 0.04% [95% CrI -0.02%至0.11%])。
  • DPP4抑制剂双药治疗中,年龄每增加30岁,HbA1c绝对降幅增加0.09%(95% CrI -0.15%至-0.03%);单药治疗(AR -0.08% [95% CrI -0.18%至0.01%])和三药治疗(AR -0.01% [95% CrI -0.06%至0.05%])无一致证据。
  • SGLT2抑制剂使用中,年龄每增加30岁,MACE相对风险降低更明显(HR 0.76 [95% CrI 0.62至0.93]);GLP-1受体激动剂使用中,年龄每增加30岁,MACE相对风险降低更少(HR 1.47 [95% CrI 1.07至2.02]);未发现一致的性别×治疗交互证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex. OBJECTIVE: To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors. DATA SOURCES AND STUDY SELECTION: The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes. DATA EXTRACTION AND SYNTHESIS: Individual participant data and aggregate data were used to estimate age × treatment interactions and sex × treatment interactions in multilevel network meta-regression models. MAIN OUTCOME AND MEASURES: Hemoglobin A1c (HbA1c) and MACEs. RESULTS: Of the 601 eligible trials identified (592 trials with 309 503 participants reported HbA1c; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168 489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI}, 0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA1c lowering with increasing age for monotherapy (AR, -0.18% [95% CrI, -0.31% to -0.05%] per 30-year increment in age) and for dual therapy (AR, -0.24% [95% CrI, -0.40% to -0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, -0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA1c lowering in older people for dual therapy (AR, -0.09% [95% CrI, -0.15% to -0.03%] per 30-year increment in age), but not for monotherapy (AR, -0.08% [95% CrI, -0.18% to 0.01%]) or triple therapy (AR, -0.01% [95% CrI, -0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex × treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists. CONCLUSIONS AND RELEVANCE: The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age × treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA1c; GLP-1 receptor agonists were more cardioprotective in younger people.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Hanlon P, Butterly E, Wei L, et al. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis. JAMA. 2025. PMID: 39899304. doi:10.1001/jama.2024.27402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。